Why Semaglutide Became 2026’s Counterfeit Case Study
In early 2026, Indian investigators linked a circulating batch of counterfeit semaglutide to a manufacturer based in Austria. Interpol flagged the network
In early 2026, Indian investigators linked a circulating batch of counterfeit semaglutide to a manufacturer based in Austria. Interpol flagged the network